Blocking PI3K p110 beta Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer

Gao, XL; Wang, YB; Ribeiro, CF; Manokaran, C; Chang, H; Von, T; Rodrigues, S; Cizmecioglu, O; Jia, SD; Korpal, M; Korn, JM; Wang, ZG; Schmit, F; Jiang, L; Pagliarini, R; Yang, Y; Sethi, I; Signoretti, S; Yuan, GC; Loda, M; Zhao, JJ; Roberts, TM

Zhao, JJ (通讯作者),Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.;Zhao, JJ (通讯作者),Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.;Gao, XL (通讯作者),Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave, Charleston, SC 29425 USA.;Roberts, TM (通讯作者),Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Biol Chem & Mol Pharmacol, 450 Brookline Ave, Boston, MA 02215 USA.;Loda, M (通讯作者),Weill Cornell Med, Dept Pathol & Lab Med, 1300 York

MOLECULAR CANCER RESEARCH, 2022; 20 (5): 673

Abstract

A common outcome of androgen deprivation in prostate cancer therapy is disease relapse and progression to castration-resistant prostate cancer (CRPC) ......

Full Text Link